Published in Oncologist on January 01, 2008
Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. J Gastrointest Surg (2008) 2.41
Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford) (2011) 1.82
Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases. Br J Surg (2014) 1.61
Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis. Gastroenterology (2016) 1.51
First clinical experience of intra-operative high intensity focused ultrasound in patients with colorectal liver metastases: a phase I-IIa study. PLoS One (2015) 1.45
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer (2012) 1.31
Preoperative imaging for hepatic resection of colorectal cancer metastasis. J Gastrointest Oncol (2012) 1.20
Shifting trends in liver-directed management of patients with colorectal liver metastasis: a population-based analysis. Surgery (2011) 1.17
Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg (2010) 1.15
Surgical management of patients with synchronous colorectal liver metastasis: a multicenter international analysis. J Am Coll Surg (2013) 1.14
What defines 'cure' after liver resection for colorectal metastases? Results after 10 years of follow-up. HPB (Oxford) (2010) 1.12
Extra-Glissonian approach in liver resection. HPB (Oxford) (2010) 1.10
Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Med (2012) 1.04
Two-stage strategy for patients with extensive bilateral colorectal liver metastases. HPB (Oxford) (2010) 1.04
The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience. HPB (Oxford) (2011) 1.00
Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases? HPB (Oxford) (2014) 0.97
A risk model to predict 90-day mortality among patients undergoing hepatic resection. J Am Coll Surg (2013) 0.95
Management of stage IV rectal cancer: palliative options. World J Gastroenterol (2011) 0.93
Single-dose radiosurgical treatment for hepatic metastases--therapeutic outcome of 138 treated lesions from a single institution. Radiat Oncol (2013) 0.92
Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol (2010) 0.91
Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget (2015) 0.90
Targeted therapies in colorectal cancer: surgical considerations. J Gastrointest Oncol (2013) 0.90
Comparative analysis of radiofrequency ablation and resection for resectable colorectal liver metastases. World J Gastroenterol (2014) 0.88
Thermal tumor ablation therapy for colorectal cancer hepatic metastasis. J Gastrointest Oncol (2012) 0.87
Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases. HPB (Oxford) (2013) 0.87
Stereotactic body radiation therapy for liver metastases from colorectal cancer: analysis of safety, feasibility, and early outcomes. Front Oncol (2012) 0.87
Effect of metabolic syndrome on perioperative outcomes after liver surgery: A National Surgical Quality Improvement Program (NSQIP) analysis. Surgery (2012) 0.86
Stereotactic body radiation therapy using the CyberKnife(®) system for patients with liver metastases. Onco Targets Ther (2014) 0.86
Post-treatment surveillance of patients with colorectal cancer with surgically treated liver metastases. Surgery (2013) 0.86
Resection of non-hepatic colorectal cancer metastasis. J Gastrointest Oncol (2012) 0.85
Liver resection for multiple colorectal liver metastases with surgery up-front approach: bi-institutional analysis of 736 consecutive cases. World J Surg (2012) 0.85
Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors. Radiat Oncol (2012) 0.84
What is the potential role of hepatic arterial infusion chemo-therapy in the current armamentorium against colorectal cancer. J Gastrointest Oncol (2012) 0.83
Visualisation of liver tumours using hand-held real-time strain imaging: results of animal experiments. Br J Radiol (2012) 0.83
Tumour growth after portal vein embolization with pre-procedural chemotherapy for colorectal liver metastases. HPB (Oxford) (2015) 0.82
Multi-modality treatment of colorectal liver metastases. World J Gastroenterol (2012) 0.82
External validation of a pre-operative nomogram predicting peri-operative mortality risk after liver resections for malignancy. HPB (Oxford) (2011) 0.81
Repeat liver resection for recurrent colorectal metastases: a single-centre, 13-year experience. HPB (Oxford) (2013) 0.80
Current state of surgical treatment of liver metastases from colorectal cancer. World J Gastrointest Surg (2011) 0.80
Limiting factors for liver regeneration after a major hepatic resection for colorectal cancer metastases. HPB (Oxford) (2013) 0.80
Outcome after repeat resection of liver metastases from colorectal cancer. Int J Colorectal Dis (2013) 0.79
Radiofrequency Ablation to Improve Survival After Conversion Chemotherapy for Colorectal Liver Metastases. World J Surg (2016) 0.79
Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. Br J Cancer (2010) 0.79
Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. Target Oncol (2015) 0.78
Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases. Int J Colorectal Dis (2011) 0.78
Intraoperative simulation of remnant liver function during anatomic liver resection with indocyanine green clearance (LiMON) measurements. HPB (Oxford) (2015) 0.78
Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases. Radiat Oncol (2016) 0.77
Utility of preoperative imaging in evaluating colorectal liver metastases declines over time. HPB (Oxford) (2010) 0.77
Safety analysis of the oncological outcome after vein-preserving surgery for colorectal liver metastases detached from the main hepatic veins. Langenbecks Arch Surg (2015) 0.77
Surgical options for initially unresectable colorectal liver metastases. HPB Surg (2012) 0.77
FIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATION. Arq Bras Cir Dig (2015) 0.76
Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection. World J Gastroenterol (2016) 0.76
Advances and new perspectives in the treatment of metastatic colon cancer. World J Gastrointest Oncol (2014) 0.76
Surgery for oligometastasis of pancreatic cancer. Chin J Cancer Res (2015) 0.76
Predictors of recurrence after a first hepatectomy for colorectal cancer liver metastases: a retrospective analysis. World J Surg Oncol (2014) 0.76
Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study. Neoplasia (2017) 0.75
Identification of liver metastases with probe-based confocal laser endomicroscopy at two excitation wavelengths. Lasers Surg Med (2016) 0.75
Fast and accurate liver volumetry prior to hepatectomy. HPB (Oxford) (2016) 0.75
Minimally Invasive Liver Surgery for Hepatic Colorectal Metastases. Curr Colorectal Cancer Rep (2016) 0.75
Factors affecting surgical margin recurrence after hepatectomy for colorectal liver metastases. Gland Surg (2016) 0.75
Intra-arterial hepatic chemotherapy for unresectable colorectal liver metastases: a review of medical devices complications in 3172 patients. Med Devices (Auckl) (2009) 0.75
Hepatic colorectal metastases involving infra-hepatic inferior vena cava in high risk patients for extended resection: an alternative method for achieving radical resection in patient with borderline liver remnant. Indian J Surg (2012) 0.75
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol (2016) 0.75
Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes. HPB (Oxford) (2016) 0.75
Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer: A Large Population Based Study. Indian J Surg Oncol (2015) 0.75
Pre-hepatectomy carcinoembryonic antigen (CEA) levels among patients undergoing resection of colorectal liver metastases: do CEA levels still have prognostic implications? HPB (Oxford) (2016) 0.75
Colorectal liver metastases: making the unresectable resectable using irreversible electroporation for microscopic positive margins - a case report. BMC Cancer (2015) 0.75
Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases. Oncol Rev (2012) 0.75
Pre-resectional inflow vascular control: extrafascial dissection of Glissonean pedicle in liver resections. Hepatobiliary Surg Nutr (2014) 0.75
Designing liver resections and pushing the envelope with resections for hepatic colorectal metastases. Indian J Surg Oncol (2013) 0.75
Debulking treatment with CT-guided percutaneous radiofrequency ablation and hepatic artery infusion of floxuridine improves survival of patients with unresectable pulmonary and hepatic metastases of colorectal cancer. Chin J Cancer (2014) 0.75
Hepatic artery injury during left hepatic trisectionectomy for colorectal liver metastasis treated by portal vein arterialization. Int J Surg Case Rep (2015) 0.75
Role of a liver-first approach for synchronous colorectal liver metastases. World J Gastroenterol (2016) 0.75
Oxaliplatin but not irinotecan impairs posthepatectomy liver regeneration in a murine model. Int J Hepatol (2011) 0.75
CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. Oncoimmunology (2016) 0.75
Weak stromal Caveolin-1 expression in colorectal liver metastases predicts poor prognosis after hepatectomy for liver-only colorectal metastases. Sci Rep (2017) 0.75
Incisional hernia after open resections for colorectal liver metastases - incidence and risk factors. HPB (Oxford) (2016) 0.75
Multidisciplinary approach of colorectal cancer liver metastases. World J Clin Oncol (2017) 0.75
Increased carcinoembryonic antigen (CEA) following neoadjuvant chemotherapy predicts poor prognosis in patients that undergo hepatectomy for liver-only colorectal metastases. Langenbecks Arch Surg (2016) 0.75
Long-term outcomes of palliation for unresectable colorectal cancer obstruction in patients with good performance status: endoscopic stent versus surgery. Surg Endosc (2016) 0.75
Effect of Age on Liver Function in Patients Undergoing Partial Hepatectomy. Dig Surg (2017) 0.75
Impact of hepatobiliary service centralization on treatment and outcomes in patients with colorectal cancer and liver metastases. Br J Surg (2017) 0.75
(18)F-FDG Uptake at the Surgical Margin after Hepatic Resection: Patterns of Uptake and Differential Diagnosis. Eur Radiol (2015) 0.75
Effects of postoperative morbidity on long-term outcome following surgery for colorectal liver metastases. World J Surg (2015) 0.75
The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg (2009) 16.82
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg (2002) 6.24
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol (2008) 3.51
Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery (2007) 3.42
Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg (2007) 3.38
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw (2009) 3.37
Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg (2009) 3.15
Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol (2008) 3.14
New staging system and a registry for perihilar cholangiocarcinoma. Hepatology (2011) 2.89
Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol (2009) 2.52
Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg (2012) 2.48
Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol (2009) 2.35
Patient readmission and mortality after colorectal surgery for colon cancer: impact of length of stay relative to other clinical factors. J Am Coll Surg (2012) 2.29
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med (2005) 2.28
Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol (2007) 2.26
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res (2012) 2.10
Achlorhydria, parietal cell hyperplasia, and multiple gastric carcinoids: a new disorder. Am J Surg Pathol (2005) 2.03
Pancreatic resection of isolated metastases from nonpancreatic primary cancers. Ann Surg Oncol (2008) 1.97
Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet (2002) 1.96
Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer (2013) 1.94
Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol (2007) 1.94
Neuroendocrine tumors. J Natl Compr Canc Netw (2012) 1.91
Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol (2004) 1.90
Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg (2007) 1.87
Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg (2009) 1.85
Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford) (2011) 1.82
Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg (2007) 1.82
Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol (2010) 1.79
A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg (2014) 1.76
Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol (2005) 1.71
Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol (2012) 1.71
Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg (2007) 1.70
Operative mortality after hepatic resection: are literature-based rates broadly applicable? J Gastrointest Surg (2008) 1.69
Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol (2012) 1.69
Predictors of survival after resection of retroperitoneal sarcoma: a population-based analysis and critical appraisal of the AJCC staging system. Ann Surg (2009) 1.68
Surgical management of solid-pseudopapillary neoplasms of the pancreas (Franz or Hamoudi tumors): a large single-institutional series. J Am Coll Surg (2009) 1.67
Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis. Ann Surg (2003) 1.66
Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg (2006) 1.65
A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol (2008) 1.64
Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg (2012) 1.64
Impact of the Comprehensive Unit-based Safety Program (CUSP) on safety culture in a surgical inpatient unit. Jt Comm J Qual Patient Saf (2010) 1.64
Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg (2011) 1.64
A proposed clinical test for monitoring fluoropyrimidine therapy: detection and stability of thymidylate synthase ternary complexes. Cancer Biol Ther (2006) 1.63
Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J (2009) 1.62
Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. Ann Surg Oncol (2003) 1.60
Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas. Ann Surg Oncol (2010) 1.60
Predicting the risk of perioperative mortality in patients undergoing pancreaticoduodenectomy: a novel scoring system. Arch Surg (2011) 1.59
The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol (2014) 1.58
Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg (2010) 1.56
Patient readmission and mortality after surgery for hepato-pancreato-biliary malignancies. J Am Coll Surg (2012) 1.55
The volume-outcomes effect in hepato-pancreato-biliary surgery: hospital versus surgeon contributions and specificity of the relationship. J Am Coll Surg (2009) 1.52
Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol (2010) 1.50
Treating patients with colon cancer liver metastasis: a nationwide analysis of therapeutic decision making. Ann Surg Oncol (2012) 1.50
Rectal cancer. J Natl Compr Canc Netw (2012) 1.49
Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg (2007) 1.46
A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. HPB (Oxford) (2012) 1.45
Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol (2009) 1.44
Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB (Oxford) (2011) 1.44
Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer (2011) 1.43